Cargando…

Cisplatin prevents breast cancer metastasis through blocking early EMT and retards cancer growth together with paclitaxel

Cancer growth is usually accompanied by metastasis which kills most cancer patients. Here we aim to study the effect of cisplatin at different doses on breast cancer growth and metastasis. Methods: We used cisplatin to treat breast cancer cells, then detected the migration of cells and the changes o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Haitao, Guo, Sen, Kim, Seung-Jin, Shao, Fangyuan, Ho, Joshua Wing Kei, Wong, Kuan Un, Miao, Zhengqiang, Hao, Dapeng, Zhao, Ming, Xu, Jun, Zeng, Jianming, Wong, Koon Ho, Di, Lijun, Wong, Ada Hang-Heng, Xu, Xiaoling, Deng, Chu-Xia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7797698/ https://www.ncbi.nlm.nih.gov/pubmed/33500735 http://dx.doi.org/10.7150/thno.46460

Ejemplares similares

Ammonium tetrathiomolybdate treatment targets the copper transporter ATP7A and enhances sensitivity of breast cancer to cisplatin
por: Chisholm, Cristine L., et al.
Publicado: (2016)

NOTCH1 activation compensates BRCA1 deficiency and promotes triple-negative breast cancer formation
por: Miao, Kai, et al.
Publicado: (2020)

FungiExpresZ: an intuitive package for fungal gene expression data analysis, visualization and discovery
por: Parsania, Chirag, et al.
Publicado: (2023)

A multicenter, randomized trial comparing efficacy and safety of paclitaxel/capecitabine and cisplatin/capecitabine in advanced gastric cancer
por: Lu, Zhihao, et al.
Publicado: (2018)

WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistance
por: Zheng, Hongping, et al.
Publicado: (2017)

Characterization of BRCA1-deficient premalignant tissues and cancers identifies Plekha5 as a tumor metastasis suppressor
por: Liu, Jianlin, et al.
Publicado: (2020)

Hederagenin potentiated cisplatin- and paclitaxel-mediated cytotoxicity by impairing autophagy in lung cancer cells
por: Wang, Kun, et al.
Publicado: (2020)

Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial
por: Stathopoulos, G. P., et al.
Publicado: (2010)

Neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation for locally advanced cervical cancer
por: Li, Jing, et al.
Publicado: (2023)

First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence.
por: Sandercock, J., et al.
Publicado: (1998)

Genetic polymorphisms and ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy
por: Tecza, Karolina, et al.
Publicado: (2015)

Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer
por: de Jong, Loek A. W., et al.
Publicado: (2023)

Inhibition of GP130/STAT3 and EMT by combined bazedoxifene and paclitaxel treatment in ovarian cancer
por: Park, Sun-Ae, et al.
Publicado: (2022)

Tumor Volume Reduction After Gemcitabine Plus Cisplatin Induction Chemotherapy in Locally Advanced Nasopharyngeal Cancer: Comparison with Paclitaxel and Cisplatin Regimens
por: Zheng, Li, et al.
Publicado: (2018)

Virchow's node together with an Irish node
por: Yoon, Ezekiel Wong Toh, et al.
Publicado: (2017)

Individualized Tumor Response Testing for Prediction of Response to Paclitaxel and Cisplatin Chemotherapy in Patients with Advanced Gastric Cancer
por: Kim, Jee Hyun, et al.
Publicado: (2010)

Linc00665 Can Predict the Response to Cisplatin-Paclitaxel Neoadjuvant Chemotherapy for Breast Cancer Patients
por: Dai, Huijuan, et al.
Publicado: (2021)

EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer
por: Haslehurst, Alexandria M, et al.
Publicado: (2012)

Combination treatment with cisplatin, paclitaxel and olaparib has synergistic and dose reduction potential in ovarian cancer cells
por: Gao, Jianwen, et al.
Publicado: (2021)

Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer.
por: Petrasch, S., et al.
Publicado: (1998)

Bi-weekly Chemotherapy of Paclitaxel and Cisplatin in Patients with Metastatic or Recurrent Esophageal Cancer
por: Cho, Sang-Hee, et al.
Publicado: (2005)

Evaluation of the paclitaxel–ifosfamide–cisplatin (TIP) combination in relapsed and/or metastatic cervical cancer
por: Kosmas, C, et al.
Publicado: (2009)

Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy
por: Goyeneche, Alicia A, et al.
Publicado: (2012)

Piperlongumine Induces Apoptosis and Synergizes with Cisplatin or Paclitaxel in Human Ovarian Cancer Cells
por: Gong, Li-Hua, et al.
Publicado: (2014)

HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells
por: Ribeiro, J. R., et al.
Publicado: (2016)

Synergistic effects of the sesquiterpene lactone, EPD, with cisplatin and paclitaxel in ovarian cancer cells
por: van Haaften, Caroline, et al.
Publicado: (2015)

Neoadjuvant cisplatin and paclitaxel modulate tumor-infiltrating T cells in patients with cervical cancer
por: Heeren, A. Marijne, et al.
Publicado: (2019)

The effect of sodium butyrate and cisplatin on expression of EMT markers
por: Mrkvicova, Alena, et al.
Publicado: (2019)

Association of the Epithelial–Mesenchymal Transition (EMT) with Cisplatin Resistance
por: Ashrafizadeh, Milad, et al.
Publicado: (2020)

EMT‐associated microRNAs and their roles in cancer stemness and drug resistance
por: Pan, Guangtao, et al.
Publicado: (2021)

Comparing Paclitaxel–Carboplatin with Paclitaxel–Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer
por: Huang, Chen-Yu, et al.
Publicado: (2020)

Evolving Evidence of the Efficacy and Safety of nab-Paclitaxel in the Treatment of Cancers with Squamous Histologies
por: Loong, Herbert H., et al.
Publicado: (2016)

Cost-effectiveness of paclitaxel plus cisplatin in advanced non-small-cell lung cancer
por: Earle, C C, et al.
Publicado: (1999)

Paclitaxel and cisplatin chemotherapy for ovarian cancer during pregnancy: case report and review of the literature
por: Serkies, Krystyna, et al.
Publicado: (2011)

Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer
por: Sun, Si, et al.
Publicado: (2014)

Concurrent chemoradiotherapy using paclitaxel plus cisplatin in the treatment of elderly patients with esophageal cancer
por: Song, Tao, et al.
Publicado: (2015)

Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer
por: Huang, Liang, et al.
Publicado: (2017)

Safety and Efficacy of Weekly Paclitaxel and Cisplatin Chemotherapy for Ovarian Cancer Patients with Hypersensitivity to Carboplatin
por: Tate, Shinichi, et al.
Publicado: (2021)

NIPEC with Single-Dose Intraperitoneal Cisplatin and Paclitaxel in Stage III Epithelial Ovarian Cancer
por: Saldanha, Elroy, et al.
Publicado: (2022)

Cancer and the Environment projects with four First Nations organizations: working together to address concerns about carcinogens in the environment
por: Palmer, Alison L., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_et2i2d7j1ma982f15hfq03hr0k